⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 15, 2024Open Access

Supplementary Figure S7 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

Aina Oliver‐Caldés Marta Español‐Rego Aintzane Zabaleta Verónica González‐Calle Sergio Navarro‐Velázquez Susana Inogés Ascensión López-Dı́az de Cerio Valentín Cabañas Nieves López‐Muñoz Paula Rodríguez‐Otero Juan Luis Reguera David F. Moreno Núria Martínez‐Cibrián Lucía López‐Corral Lorena Pérez-Amill Beatriz Martín-Antonio Laura Rosiñol Joan Cid Natalia Tovar Joaquín Sáez‐Peñataro Miriam López-Parra Eulàlia Olesti Elena Guillén Sara Varea Luis Gerardo Rodríguez‐Lobato Anthony M. Battram Marta Sonia González Andrés Sánchez‐Salinas Europa Azucena González‐Navarro Valentín Ortiz‐Maldonado Julio Delgado Felipe Prósper Manel Juan Joaquín Martínez‐López José M. Moraleda María‐Victoria Mateos Álvaro Urbano-Ispizúa Bruno Paiva Mariona Pascal Carlos Fernández de Larrea

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure 7. Persistence of ARI0002h in the peripheral blood according to prior drug refractoriness and allogeneic stem cell transplantation

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Oliver‐Caldés et al. (2024) studied this question.

synapsesocial.com/papers/68e6a13db6db643587624d9c https://doi.org/10.1158/1078-0432.25826705.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S7 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024
2Supplementary Figure S3 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024
3Supplementary Figure S3 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024
4Supplementary Figure S6 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024
5Supplementary Figure S6 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024

More related papers

Supplementary Figure S5 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024
Supplementary Figure S5 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024
Supplementary Figure S8 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma2024